Post by Isaac TW

Key developments shaping the CVRM landscape this week: 🏢 Business Updates 💊hims & hers could benefit as employers reduce GLP-1 coverage, accelerating the shift to cash-pay obesity treatments. 🏪 GoodRx launched a manufacturer-funded reimbursement model to support independent pharmacies dispensing GLP-1 therapies. 🩺 TWL launched a virtual tirzepatide platform integrating clinical evaluation and insurance support. 📱 Zealthy expanded its obesity platform with provider access to Zepbound. 🚚 Eli Lilly and Company launched LillyDirect UK for home delivery of Mounjaro. 🏭 Eli Lilly and Company expanded manufacturing investments in China to support oral GLP-1s and tirzepatide. 💳 CMS launched the Medicare GLP-1 Bridge Program with fixed monthly copays for eligible patients. 👤 Diamyd Medical appointed Mathias Skalmstad as CFO. 💰 Ollin Biosciences raised $330M to advance Phase 3 development of IBI324 for DME and wet AMD. 🤝 Partnerships & M&A 🛒 Novo Nordisk partnered with Costco Pharmacy to expand self-pay access to Wegovy and Ozempic. 🔄 Sangamo Therapeutics, Inc. Therapeutics filed for Chapter 11 while agreeing asset sales to Eli Lilly and Astellas. 🧪 Clinical Trials 🫀 Survodutide achieved strong Phase 3 liver-fat reduction in MASLD. ❤️ AnaCardio's AC01 showed encouraging safety and cardiac function improvements in HFrEF. 💉 Vivani Medical received approval to begin the SLIM-1 trial of its semaglutide implant. 📊 Wave Life Sciences advanced WVE-007 into Phase 2a after promising early obesity data. 🚀 Viking Therapeutics, Inc. initiated first-in-human testing of VK3019 for obesity. 📉 CORXEL Pharmaceuticals reported up to 11.5% weight loss with oral GLP-1 candidate CX11. ✅ Ascletis Pharma Inc. Pharma received FDA clearance to begin Phase 1 testing of ASC35. ✅ Regulatory & Market Access 📜 CanFite BioPharma secured a Japanese patent for Namodenoson in obesity. 🧬 Ionis Pharmaceuticals, Inc. expanded the U.S. label for Tryngolza. 🏅 Imbria Pharmaceuticals received FDA Orphan Drug Designation for ninerafaxstat. 📋 Galectin Therapeutics aligned with the FDA on the Phase 3 pathway for belapectin. 🇬🇧 Teplizumab (Sanofi) is now available through the NHS to delay Type 1 diabetes onset. 👶 MannKind Corporation received Breakthrough T1D funding for its pediatric Afrezza trial. 📈 Market Insights 🏆 Evaluate forecasts Lilly's tirzepatide franchise will become the world's best-selling medicine by 2032.